In Novo Nordisk's studies, patients taking the drug maintained weight loss after four years and were helped by its heart health benefits, which could strengthen the case for insurers to cover the cost of Wegovy.
Ozempic, Trulicity and Mounjaro were first approved to treat diabetes, however, in the last three years, the FDA has approved rebranded versions of Mounjaro and Ozempic for weight loss, leading demand – and prices – to skyrocket.
Benefits advisors play a crucial role in safeguarding the health and financial wellbeing of millions of Americans, making their role more vital than ever in the face of recent significant legal and economic challenges.
Pharmacy benefit manager Optum Rx plans to launch Clear Trend Guarantee in 2025 to allow employers and health insurers to more easily manage their drug spending, while creating more predictability for patients around costs.
Doctors, health care systems, providers, public health experts and community leaders will all need to work together to create a new model of equitable diabetes care.